COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study
e202312111
Keywords:
Neutralizing antibodies, COVID-19, SARS-CoV-2, Serological test, Lateral flow assay, Lateral flow immunochromatography.Abstract
BACKGROUND // Neutralizing antibodies against SARS-CoV-2 have shown to be an effective tool for the analysis of the immunity generated against COVID-19. Numerous seroprevalence studies carried out in different groups have made it possible to draw a global map of vaccination coverage through the use of rapid lateral flow immunochromatography serological tests for clinical and epidemiological purposes. The objective of our study was to determine the degree of immunity against SARS-CoV-2 associated with the presence of neutralizing antibodies in administrative staff, teachers and students at the University of Alicante by means of a rapid serological test and to learn about their experience with vaccination against COVID-19.
METHODS // A cross-sectional epidemiological study was designed, based on the prevalence of antibodies against the S protein (spike) of SARS-CoV-2. A total of 888 people participated. The study was carried out with a single test (July 6 to July 22, 2021). Using logistic regression, adjusted Odds Ratios were calculated according to sex, age, type of vaccine, number of vaccine doses received, complete vaccination schedule, and having had COVID-19.
RESULTS // The vaccines received mostly were Vaxzevria® and Comirnaty®, with 73.3% between both, although 67.2% presented a complete regimen. The results of the OJABIO rapid neutralizing antibody test gave a positive result in 61.4% of the sample. There was a high association between the variables COVID-19 infection, two doses of vaccine, Spikevax® or Comirnaty® vaccine, and eighteen/twenty-nine years old group with a positive result on the OJABIO test. A total of 712 subjects answered the parallel survey (80%) on adverse effects and preferences between the different vaccines against COVID-19.
CONCLUSIONS // The vaccination status against COVID-19 in the university community after six months of the start of national immunization strategies reflects low coverage despite the excellent willingness to get vaccinated. Neutralizing antibodies (NAb) rapid tests can be useful to guide immunization strategies and decide when to administer new booster doses.
Downloads
References
WHO Coronavirus (COVID-19) Dashboard. Disponible en: https://covid19.who.int/ (consultado el 22 de agosto 2023).
Sidiq Z, Hanif M, Dwivedi KK, Chopra KK. Benefits and limitations of serological assays in COVID-19 infection. Indian J Tuberc. 2020;67(4S):S163-S166. doi: https://dx.doi.org/10.1016/j.ijtb.2020.07.034
Bostan M, Ataman M, Bostan IS, Bleotu C. Targets and assay types for COVID-19 diagnosis. J Immunoassay Immunochem. 2020;41(6):946-959. doi: https://dx.doi.org/10.1080/15321819.2020.1862866
Ernst E, Wolfe P, Stahura C, Edwards KA. Technical considerations to development of serological tests for SARS-CoV-2. Talanta. 2021;224:121883. doi: https://dx.doi.org/10.1016/j.talanta.2020.121883
Taleghani N, Taghipour F. Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art. Biosens Bioelectron. 2021;174:112830. doi: https://dx.doi.org/10.1016/j.bios.2020.112830
European Medicines Agency (EMA). Disponible en: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised (consultado el 5 de mayo de 2023).
Agarwal R, Gopinath G. A Proposal to End the COVID-19 Pandemic. En: IMF Staff Discussion Note, International Monetary World, 2021; 001.
Oehler RL, Vega VR. Conquering COVID: How Global Vaccine Inequality Risks Prolonging the Pandemic. Open Forum Infect Dis. 2021;8(10):ofab443. doi: https://dx.doi.org/10.1093/ofid/ofab443
Estrategia de vacunación frente a COVID-19 en España. Actualización 4. 26 de febrero de 2021. Disponible en: https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/nCov/vacunaCovid19.htm (consultado el 22 de agosto de 2023).
Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur J Clin Invest. 2020;50(12):e13423. doi: https://dx.doi.org/10.1111/eci.13423
Matos CCSA, Barbieri CLA, Couto MT. COVID-19 and its impact on immunization programs: reflections from Brazil. Rev Saude Publica. 2020;54:114. doi: https://dx.doi.org/10.11606/s1518-8787.2020054003042
Kim DS, Rowland-Jones S, Gea-Mallorquí E. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Front Immunol. 2020;11:571481. doi: https://dx.doi.org/10.3389/fimmu.2020.571481
Wisnewski AV, Campillo Luna J, Redlich CA. (2021) Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 16(6): e0249499. https://dx.doi.org/10.1371/journal.pone.0249499
Racine-Brzostek SE, Yee JK, Sukhu A et al. Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight. 2021;6(20):e151477. doi: https://dx.doi.org/10.1172/jci.insight.151477
Doria-Rose N, Suthar MS, Makowski M et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2022 Feb 3;386(5):500]. N Engl J Med. 2021;384(23):2259-2261. doi: https://dx.doi.org/10.1056/NEJMc2103916
Coppeta L, Somma G, Ferrari C et al. Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19. Vaccines (Basel). 2021;9(9):947. Published 2021 Aug 25. doi: https://dx.doi.org/10.3390/vaccines9090947
Estrategia de vacunación frente a COVID19 en España. Actualización 11. 8 de febrero 2022. Disponible en: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/Actualizaciones_Estrategia_Vacunacion/docs/COVID-19_Actualizacion11_EstrategiaVacunacion.pdf (consultado el 24 de abril de 2023).
Tuells J, Egoavil CM, Pena Pardo MA et al. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). Int J Environ Res Public Health. 2021;18(4):1908. doi: https://dx.doi.org/10.3390/ijerph18041908
Rostami A, Sepidarkish M, Leeflang MMG et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331-340. doi: https://dx.doi.org/10.1016/j.cmi.2020.10.020
Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120-134. doi: https://dx.doi.org/10.1016/j.jhin.2020.11.008
Venugopal U, Jilani N, Rabah S et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic. Int J Infect Dis. 2021;102:63-69. doi: https://dx.doi.org/10.1016/j.ijid.2020.10.036
Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. Eur J Clin Invest. 2021;51(5):e13554. doi: https://dx.doi.org/10.1111/eci.13554
Montesinos I, Gruson D, Kabamba B et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 2020;128:104413. doi: https://dx.doi.org/10.1016/j.jcv.2020.104413
Tuells J, Parra-Grande M, Santos-Calle FJ et al. Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA. Vaccines (Basel). 2022;10(4):510. doi: https://dx.doi.org/10.3390/vaccines10040510
Bubar KM, Reinholt K, Kissler SM et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371(6532):916-921. doi: https://dx.doi.org/10.1126/science.abe6959
Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. doi: https://dx.doi.org/10.1186/s12979-019-0164-9
Centers for Disease Control and Prevention. Possible side-effects from vaccines. Disponible en: http://www.cdc.gov/vaccines/vac-gen/side-effects.htm (consultado el 10 de mayo 2023).
Saxena SK, Kumar S, Ansari S et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738-1744. doi: https://dx.doi.org/10.1002/jmv.27524
Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021;371(6530):741-745. doi: https://dx.doi.org/10.1126/science.abe6522
Actualización de la situación epidemiológica de las variantes de SARS-CoV-2 en España. 6 de Junio de 2023. Disponible en: sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20230606.pdf (consultado el 22 de agosto 2023).
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Ana C. Montagud, Nancy Vicente-Alcalde, Eva M. Gabaldón-Bravo, José Antonio Hurtado-Sánchez, Emilia Montagud, Cecilia M. Egoavil, Enrique Chavarría-Alarcón, Pablo Caballero, José Tuells
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
